Skip to main content
COVID-19

Osteoporosis Management in Women Who Had a Fracture (OMW)

HEDIS Measure

Osteoporosis Management in Women Who Had a Fracture (OMW)

Line of business: Medicare

Data Collection Method: Administrative

Measure Description

The percentage of women 67–85 years of age who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.

Numerator Compliance

Appropriate testing or treatment for osteoporosis after the fracture defined by any of the following criteria:

  • A BMD test in any setting, on the IESD or in the 180-day (6-month) period after the IESD.
  • If the IESD was an inpatient stay, a BMD test during the inpatient stay.
  • Osteoporosis therapy on the IESD or in the 180-day (6- month) period after the IESD.
  • If the IESD was an inpatient stay, long-acting osteoporosis therapy during the inpatient stay.
  • A dispensed prescription to treat osteoporosis on the IESD or in the 180-day (6-month) period after the IESD.

IESD - Index Episode Start Date. The earliest episode date during the intake period that meets all eligible population criteria.

Best Practices

  • Reference The American College of Obstetricians and Gynecologists' Osteoporosis FAQ: www.acog.org/en/Patient%20Resources/FAQs Women's Health/Osteoporosis
  • Reference Healthy People gov's Osteoporosis to Prevent Fracture: Screening https://www.healthypeople.gov/2020/tools- resources/evidence-basedresource/osteoporosis-to-prevent- fractures-screening

OSTEOPOROSIS MEDICATIONS

Description Prescriptions
Bisphosphonates Alendronate, Alendronate-cholecalciferol, Ibandronate, Risedronate, Zoledronic acid
Other agents Abaloparatide, Denosumab, Raloxifene, Romosozumab, Teriparatide